Health Decisions hopes Management View will cut monitoring costs

By Gareth Macdonald

- Last updated on GMT

Related tags: Contract research organization, Clinical trial

US CRO Health Decision says the new “Monitor View” module for its HD360 trial management system makes assessing study site performance an easier and more cost effective process.

The North Carolina contract research organisation (CRO) estimates that site monitoring, including travel and assessment, can account for up to 80 of a trial’s budget, particularly given the growth of multi-country studies.

The module, which is designed to streamline the monitoring process, collects and presents site performance data to sponsors via the web in an approach that, the firm claims, “[produces] faster, more accurate results with fewer wasted resources.”

It also schedules inspections based on the amount of work conducted at a particular site, thereby avoiding arbitrary visits to locations that may not have amassed a significant quantity of data.

Health Decisions COO Rick Farris explained that efficiency was the key motivation for developing the new extension.

For a clinical trial to be truly efficient, every person working on it must have access to the right information, which includes both performance data and meaningful analysis, as quickly as possible​.”

“By granting monitors the ability to continuously refine the trial’s operations within the limits of their role, HD360˚ and our Agile Clinical Development platform allow every study to benefit from efficiency-boosting adaptive techniques with no added risk to data integrity or patient safety.”

He went on to say that Monitor View is already providing benefits for trial monitors, both in day to day operations and overall trial performance.

Sites, investigators and sponsors

The new module is the second extension of the HD360 system after the aptly named clinical investigator monitoring tool “Investigator View”, which was launched earlier this year and has since been upgraded with “sleeker reports” and “search filters.”

The third and final update, scheduled for release in 2010, “Sponsor View” is designed to enhance reporting and data analysis and will, according to head of Heal Decisions IT department Maurice Hagar, complete HD360 as a trial management hub.

“Each study role, investigator site, monitor, sponsor and every function in between, will be equipped with information to more actively contribute to the study’s overall success.

“The end result is an unbroken stream of data handled as efficiently as possible from start-up to database lock and beyond, letting us take advantage of every opportunity to make our sponsors’ programs run faster and more smoothly.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more